Core Viewpoint - RCI Hospitality Holdings, Inc. is facing a class action lawsuit due to allegations of tax fraud and bribery, which resulted in misleading statements about the company's business and legal risks [3][4]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from December 15, 2021, to September 16, 2025, the defendants engaged in tax fraud and bribery to conceal this fraud [3]. - It is claimed that these actions led to an understatement of the legal risks facing the company and that the defendants' statements regarding the business, operations, and prospects were materially false and misleading [3]. Class Action Details - Shareholders who purchased shares during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action is November 20, 2025, and there is no cost or obligation to participate [4]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices, emphasizing the importance of responsible business conduct [5].

Core Points - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with specific deadlines for filing lead plaintiff motions [1] RCI Hospitality Holdings, Inc. (NASDAQ: RICK) - Class period is from December 15, 2021, to September 16, 2025, with a lead plaintiff deadline of November 20, 2025 [2] - Allegations include materially false and misleading statements regarding tax fraud and bribery, which resulted in an understatement of legal risks and misleading positive statements about the company's business [2] Fortinet, Inc. (NASDAQ: FTNT) - Class period is from November 8, 2024, to August 6, 2025, with a lead plaintiff deadline of November 21, 2025 [3] - Allegations include misleading statements about the refresh cycle of products, lack of clarity on upgradeable firewalls, and misrepresentation of the refresh momentum, leading to materially misleading positive statements about the company's prospects [3] Molina Healthcare, Inc. (NYSE: MOH) - Class period is from February 5, 2025, to July 23, 2025, with a lead plaintiff deadline of December 2, 2025 [4] - Allegations include failure to disclose adverse facts regarding medical cost trend assumptions, dependency on low utilization of services for growth, and the likelihood of cutting financial guidance for fiscal year 2025, resulting in materially misleading positive statements about the company's operations [4]

Core Points - A class action lawsuit has been filed against James Hardie Industries plc for alleged securities fraud and unlawful business practices [2] - Investors have until December 23, 2025, to request appointment as Lead Plaintiff if they purchased James Hardie securities during the Class Period [2] - The lawsuit follows a significant decline in sales, with North America Fiber Cement sales dropping by 12% due to customer destocking [4] Company Performance - On August 19, 2025, James Hardie disclosed a 12% decline in North America Fiber Cement sales, attributed to customer destocking identified by the company in April and May [4] - Following this announcement, James Hardie's stock price fell by $9.79 per share, or 34.44%, closing at $18.64 per share on August 20, 2025 [5] Legal Context - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the class action against James Hardie [6] - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [6]

Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 29, 2024, to January 6, 2025, related to the company's merger with Koito Manufacturing Co., Ltd. [1] Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased or sold Cepton common stock during the specified Class Period [1] - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff for the class [2] Group 2: Company Background - Cepton is an electronics company focused on high-performance lidar technologies for the Automotive and Smart Infrastructure markets, offering various lidar systems and software [4] - Koito Manufacturing Co., Ltd. invested $200 million in Cepton in July 2023, acquiring 30.1% of Cepton's voting power and two board seats [5] Group 3: Merger Information - Cepton accepted Koito's bid of $3.17 per share in July 2024, which closed on January 7, 2025, providing cash to all outstanding Cepton shareholders [6] - The merger was described as a strategic milestone for Cepton, aimed at enhancing its lidar technology commercialization [6] Group 4: Allegations in the Complaint - The Complaint alleges that Cepton's executives made materially false and misleading statements regarding the company's operations and compliance, including failing to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition [6][8] - It is claimed that the Board did not adequately explore this third-party offer and misled shareholders regarding the terms of the Koito Acquisition [6][8] - Allegations also include conflicts of interest involving Cepton's CEO, who is said to have prioritized personal economic interests over those of the shareholders [8]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 26, 2024, to September 17, 2025, seeking damages for misleading statements regarding the company's products and operations [1][5]. Company Overview - DexCom is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management, with key products including the Dexcom G6 and G7 systems launched in 2018 and 2023, respectively [4]. Allegations and Misleading Statements - The lawsuit alleges that DexCom made materially false and misleading statements about the G6 and G7 systems, including unauthorized design changes that compromised their reliability and safety, leading to increased health risks for users [5]. - Specific allegations include overstated claims about the G7's accuracy and functionality, downplaying the severity of issues with the devices, and failing to disclose the risk of regulatory scrutiny and potential legal repercussions [5]. Regulatory Issues - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management concerns, which led to a significant drop in stock price [6]. - The FDA later published the warning letter, confirming that the G6 and G7 products were "adulterated" due to modifications made without prior approval, resulting in larger inaccuracies and increased risks for users [7]. Market Reactions - Following the FDA's warning and subsequent reports of issues with the G7, DexCom's stock experienced notable declines, including a drop of $7.12 per share (9.15%) on March 10, 2025, and further declines after Oppenheimer downgraded the stock rating due to concerns about the G7's performance [6][8][9]. - A report by Hunterbrook highlighted severe health risks associated with the G7, linking inaccuracies to hospitalizations and fatalities, which further impacted DexCom's stock price, resulting in a drop of $8.99 per share (11.76%) [10][11].

Core Points - A securities fraud class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of the Securities Exchange Act of 1934 [3][4] - The lawsuit claims that the company made misrepresentations regarding its drug candidate, sonelokimab (SLK), which was marketed as superior to competing monoclonal antibody drugs [4] Summary by Sections Lawsuit Details - The lawsuit was initiated on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3] - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, with no fees or expenses required from shareholders [5] Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [6]

Core Viewpoint - Baxter International Inc. is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding the safety of its Novum IQ Large Volume Pump, which is claimed to have systemic issues that could endanger patients [3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Baxter and certain senior officers [3]. Group 2: Investor Participation - Investors who wish to serve as lead plaintiffs must file papers by December 15, 2025, and can act on behalf of other class members [5]. - Participation as a lead plaintiff is not required to share in any potential recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company providing managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was monitoring utilization patterns to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2%, revising it to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, regarding full-year adjusted earnings expectations of no less than $19.00 per diluted share, Molina's stock price fell by $32.03, or 16.8%, from $190.25 to $158.22 per share [4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational therapeutic sonelokimab [3]. Clinical Trials and Data - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses for patients and a competitive edge for sonelokimab over traditional monoclonal antibody treatments [4]. - However, the lawsuit alleges that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Company Overview - Stride, Inc. provides proprietary and third-party online curriculum, software systems, and educational services [3]. Recent Developments - On September 10, 2025, the Gallup-McKinley County Schools Board of Education filed a verified complaint against Stride, alleging fraud, deceptive trade practices, and systemic violations of law, particularly affecting Native American students [4]. - On October 29, 2025, Stride issued a negative annual revenue forecast, citing difficulties in enrolling new students, which led to a more than 50% drop in its share price [4]. Legal Investigation - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Stride, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1].